Fortress Biotech Inc

NASDAQ:FBIOUnited States

Yesterday

Show headlines and story abstract

• Mustang Bio Announces Pricing of $4 Million Public Offering, from 6 hours ago by GlobeNewswire

  6 hours ago by GlobeNewswire
  Companies Mentioned: FBIO, MBIO

• Mustang Bio Announces Pricing of $4 Million Public Offering, from 6 hours ago by Dow Jones

  6 hours ago by Dow Jones
  Companies Mentioned: FBIO, MBIO
  
  Mustang Bio Announces Pricing of $4 Million Public Offering
  
  WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to 16,877,638 shares of common stock, Series A-2 warrants to purchase up to 16,877,638 shares of common stock and Series A-3 warrants to purchase up to 16,877,638 shares of common stock, at a combined public offering price of $0.237 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $0.237 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series A-1 warrants will expire five years from the date of stockholder approval, the Series A-2 warrants will expire twenty-four months from the date of stockholder approval and the Series A-3 warrants will expire nine months from the date of stockholder approval. The closing of the offering is expected to occur on or about May 2, 2024, subject to the satisfaction of customary closing conditions.
  

• Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds, from 18 hours ago by GlobeNewswire

  18 hours ago by GlobeNewswire
  Companies Mentioned: FBIO, ATXI

• Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds, from 18 hours ago by Dow Jones

  18 hours ago by Dow Jones
  Companies Mentioned: FBIO, ATXI
  
  Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
  
  MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company's common stock. The exercised warrants are comprised of warrants to purchase shares of common stock originally issued by Avenue on October 11, 2022, each having an exercise price of $116.25 per share, Series A and Series B warrants to purchase shares of common stock originally issued by Avenue on November 2, 2023, each having an exercise price of $22.545 per share, and warrants to purchase shares of common stock originally issued by Avenue on January 9, 2024, each having an exercise price of $22.545 per share. The warrant holders agreed to exercise these warrants for cash at a reduced exercise price of $6.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-267206 and 333-274562) and Form S-3 (No. 333-276671). The gross proceeds to Avenue from the exercise of the warrants are expected to be approximately $4.4 million, prior to deducting placement agent fees and offering expenses. The closing of the warrant exercise transaction is expected to occur on or about May 1, 2024, subject to satisfaction of customary closing conditions.